All In Biotech

Drug Trial Radar · NCT03944772

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.

Last checked: Nov 20, 2026Latest source record: Jan 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

247

Actual

Start

Jun 25, 2019

Primary completion

May 6, 2025

Study completion May 6, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 10, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • OsimertinibDrug

    Osimertinib given orally at 80 mg once daily

  • SavolitinibDrug

    Savolitinib will be given orally at 300 mg or 600mg once daily

  • GefitinibDrug

    Gefitinib given orally at 250 mg once daily

  • NecitumumabDrug

    Necitumumab given IV at 800 mg on Day 1 and Day 8 of every 3-week cycle

  • DurvalumabDrug

    Durvalumab given IV at 1500 mg on Day 1 of every cycle

  • CarboplatinDrug

    Carboplatin given IV on Day 1 of every 21-day cycle for up to 6 cycles

  • PemetrexedDrug

    Pemetrexed given IV at 500 mg/m2 body BSA on Day 1 of every cycle

  • AlectinibDrug

    Alectinib given orally at 600mg twice daily and for Japanese patients at 300mg twice daily.

  • SelpercatinibDrug

    Selpercatinib given orally at 160mg twice daily

  • SelumetinibDrug

    Selumetinib given orally at 75 mg twice daily for 4 days, followed by 3 days off treatment

  • EtoposideDrug

    Etoposide 80-100 mg/m2 given IV on day 1, 2 and 3 of every 21-day cycle for up to 4 cycles.

  • CisplatinDrug

    Cisplatin 75-80 mg/m2 given IV on days 1 of each cycle

  • Datopotamab deruxtecanDrug

    Datopotamab deruxtecan given IV at 4 or 6 mg/kg on Day 1 of every 3-week cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Measured from first dose until confirmed response or progression. For each patient this is expected to be 3 months on average

Locations

47 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California

  • Research Site

    Los Angeles, California

  • Research Site

    Sacramento, California

  • Research Site

    Santa Monica, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Chicago, Illinois

  • Research Site

    Baltimore, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Portland, Oregon

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Houston, Texas

  • Research Site

    Seattle, Washington

  • Research Site

    Odense C, Denmark

  • Research Site

    Catania, Italy

  • Research Site

    Naples, Italy

  • Research Site

    Orbassano, Italy

  • Research Site

    Padova, Italy

  • Research Site

    Varese, Italy

  • Research Site

    Chūōku, Japan

  • Research Site

    Fukuoka, Japan

  • Research Site

    Kōtoku, Japan

  • Research Site

    Nagoya, Japan

  • Research Site

    Osaka, Japan

  • Research Site

    Wakayama, Japan

  • Research Site

    Amsterdam, Netherlands

  • Research Site

    Amsterdam, Netherlands

  • Research Site

    Maastricht, Netherlands

  • Research Site

    Nijmegen, Netherlands

  • Research Site

    Rotterdam, Netherlands

  • Research Site

    Drammen, Norway

  • Research Site

    Oslo, Norway

  • Research Site

    Trondheim, Norway

  • Research Site

    Seongnam-si, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.